This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Henry Schein (HSIC) Matches Q4 Earnings Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 0% and 0.45%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Henry Schein (HSIC) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Henry Schein (HSIC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) dental business is likely to have gained in Q4 from the acquisition of Midway Dental.
Henry Schein (HSIC) Expands Dental Offerings With New Pact
by Zacks Equity Research
Henry Schein's (HSIC) latest deal expands its offering in several fast-growing product segments, including clinical software and oral surgery and orthodontic products.
Henry Schein's (HSIC) New Tie-Up to Improve Patient Outcome
by Zacks Equity Research
Henry Schein's (HSIC) recent deal with VideaHealth is expected to aid dentists in proving greater transparency to patients, thus making better treatment recommendations and improving case acceptance.
Henry Schein's (HSIC) New Deal to Improve Patient Outcome
by Zacks Equity Research
Henry Schein's (HSIC) recent deal with Rimidi is expected to aid healthcare professionals in enhancing chronic disease management.
Henry Schein (HSIC) Q3 Earnings In Line, 2022 Sales View Down
by Zacks Equity Research
Severe currency headwinds and lower sales of PPE and COVID-19 test kits affect Henry Schein's (HSIC) top line in Q3.
Henry Schein (HSIC) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 0.88% and 4.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks Due to Report Earnings on Nov 1: MCK, CTLT & More
by Debanjana Dey
MedTech companies' Q3 results are likely to reflect strength in customer demand. Let's see how MCK, CTLT, ECL, ABMD, HSIC and IDXX are placed ahead of their earnings releases.
Henry Schein (HSIC) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Henry Schein (HSIC) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
We expect the Condor Dental buyout to have a beneficial impact on Henry Schein's (HSIC) results in the to-be-reported quarter.
Why Is Henry Schein (HSIC) Down 1.5% Since Last Earnings Report?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Henry Schein (HSIC) Inks Deal to Acquire Midway Dental Supply
by Zacks Equity Research
Henry Schein's (HSIC) acquisition of Midway Dental Supply complements its efforts to offer products and services that deliver more effective, high-quality patient care.
Henry Schein (HSIC) Q2 Earnings Top Estimates, '22 EPS View Up
by Zacks Equity Research
Henry Schein (HSIC) reports better-than-expected Q2 earnings with impressive sales growth across the Medical and Technology and Value-added Services segments.
Henry Schein (HSIC) Beats Q2 Earnings Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 3.57% and 2.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Can Henry Schein (HSIC) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Henry Schein (HSIC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Merit Medical (MMSI) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 25.86% and 4.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Beat Likely for AmerisourceBergen (ABC) in Q3 Earnings?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal third-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
Analysts Estimate McKesson (MCK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Henry Schein (HSIC) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) Q2 performance will likely reflect continued strength in its dental and medical businesses.
Henry Schein (HSIC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Henry Schein's (HSIC) New Buyout Expands Its Switzerland Base
by Zacks Equity Research
Henry Schein (HSIC) serves the Swiss dental implant market through its Basel-based division, Camlog Biotechnologies GmbH, since 2004.
Henry Schein (HSIC) Global Dental Arm Rebounds Amid Cost Woes
by Zacks Equity Research
Henry Schein's (HSIC) widespread network and channel mix along with favorable long-term trends in the dental business look encouraging.
Here's Why Henry Schein (HSIC) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Henry Schein (HSIC) Inks New Deal to Acquire Condor Dental
by Zacks Equity Research
Henry Schein's (HSIC) acquisition of a Switzerland-based dental distribution company will strengthen its presence in the attractive European market.